预约演示

Helsinn and Angelini Pharma renew AULIN and MESULID distribution deal

2024-05-28

交易

引进/卖出上市批准优先审批

The medicines are indicated for usage as a second line treatment option for acute pain and primary dysmenorrhea. Credit: Kmpzzz / Shutterstock.com.

Helsinn Group has renewed a distribution and licence agreement with Angeliniacute painr theprimary dysmenorrheaf AULIN and MESULID (Nimesulide) to treat acute short-term pain in six European countries.

Helsinn Groupes covered under the renewed deal include Bulgaria, theAngelini Pharma, Hungary, Poland, Romania andAULINSlovaMESULIDliNimesulide acute short-term pain

The non-selective, non-steroidal anti-inflammatory drugs AULIN and MESULID are offered on prescription as an oral tablet and granules for oral suspension.

They are indicated for usage as a second-line treatment oAULIN for MESULIDain and primary dysmenorrhea.

AULIN gel, also marketed under the brand name AulinDol, is availablacute painriptiprimary dysmenorrheaer.

AULIN gelFDA accepts Sanofi’s Sarclisa sBLA for priority review

South KorFDAs MFDS apSanofi EiSarclisaen’s LEQEMBI for Alzheimer’s

It is intended to provide symptomatic relief of pain linked to sprains and acute traumatic tendinitis.

Helsinn Group CEO Dr Melanie Rolli stated: LEQEMBI pleased to have signed this agreement with Angelini and honoured to maintain our ongoing collaboration.

“Our long-standing partnership with Angelini exemplifies how Helsinn fosters relationships and alliances to deliver essential products to patients. We appreciate their extensive reach in these countries, which enables patient access to this much-needed treatment.”

Angelini Pharma International Operations executipainice-president Erik Lommacute traumatic tendinitishted to renew our partnership with Helsinn.

Helsinn Groupration is built on a foundation of mutual trust, highlighted by our shared commitAngeliniprofessional excellence, in-depth product knowledge, and high-quality service. This alliance is crucial for both parties and represents a strong business relationship.”

In May 2023, Angelini Pharma and JCRAngelinieuticals signed aHelsinn development and commercialisation agreement focused on developing novel biologic therapies.

Angelini Pharma International Operationso technology to address epilepsy.Helsinn

JCR Pharmaceuticals received research expense reimbursements, upfront payments and milestone payments of $505.5m, in addition to tiered royalties on net product sales post-approval.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构